FDA 483 - Daiichi Sankyo, Inc. - August 01, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Daiichi Sankyo, Inc. in Basking Ridge, NJ, revealed significant deficiencies in their Risk Evaluation and Mitigation Strategy (REMS) program. The firm failed to identify and address non-compliant healthcare providers and ensure prescribers reported serious adverse events. Additionally, the company did not maintain adequate drug distribution and dispensing records to ensure restricted distribution, allowing product to be dispensed by non-certified prescribers and transferred to non-certified locations.
ID · f0850f83-06e7-4dd5-8243-ba2ce8a276cc